Ilara Health, the health-tech company which provides point of care diagnostic testing to small primary care clinics in Kenya, has received a USD$1,120,262 grant from the Bill & Melinda Gates Foundation. The grant will be used to develop effective antenatal care (ANC) interventions and tech based solutions for pregnant women unable to access essential services during the COVID-19 pandemic.
Emilian Popa, CEO and Co-founder of Ilara Health while receiving the grant, said; “We are incredibly excited to receive support from the Bill & Melinda Gates Foundation to improve Kenya’s maternal health outcomes and promote Ilara Health’s core mission of improving access to diagnostics countrywide. This grant underscores the acute need for the continuation of essential ANC services during the COVID-19 pandemic and we hope to see a great reduction in poor maternal and neonatal health outcomes through its implementation in these low-resource peri-urban areas.”
Ilara Health, in tandem with the Kisumu Ministry of Health and the Kenya Medical Research Institute, will leverage a network of local primary care facilities, telemedicine, and home-based health worker consultations to ensure safe continuity of life-saving maternal care during the pandemic and beyond.
The grant is expected to reach approximately 4,000 low income pregnant women in peri-urban Kisumu county, addressing a significant drop in ANC attendance at large health facilities as concerns for possible COVID-19 transmission grow in these hotspots. Currently less than 3% of women in Kenya complete the World Health Organization recommended eight ante-natal care appointments, which reduces the likelihood of maternal deaths and stillbirths.
Maternal mortality in Kenya is already high with 342 maternal deaths per 100,000 recorded in 2017; however, Kisumu County has one of the highest rates of maternal death at 595 deaths per 100,000 live births in 2019.
Ilara Health and its partners will work to ensure essential ANC is available at small local clinics. The project aims to improve access to diagnostics locally and, through Ilara Health’s technology platform and diagnostic tools, the team will reach pregnant women at their local clinics, individual homes, or remotely collectively providing safe, COVID-free, high-quality care to both mother and baby.
Additionally, through its partnership with Butterfly Network, the company behind the telemedicine-enabled Butterfly iQ, a separate set of small facilities without in-house sonographers will be linked to imaging specialists so scans that are carried out locally can be read and diagnosed remotely in real time, so patients receive immediate feedback. If successful, this feature will be rolled out across the larger project to improve the availability of ultrasounds across peri-urban areas.
The project also aims to drive community awareness on the importance of ANC services and ANC attendance in improving maternal and neonatal health outcomes for longer-term improvement in care.
